Supriya Lifescience Ltd (SUPRIYA) — shareholding pattern, promoter holding, financials and share price

About Supriya Lifescience Ltd (SUPRIYA)

Supriya Lifescience Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SUPRIYA and on the BSE under scrip code 543434. Its ISIN is INE07RO01027.

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]

Supriya Lifescience Limited is an India‑based integrated API manufacturer and exporter focused on niche therapeutic APIs including anesthetics, anti‑histamines, vitamins and anti‑asthmatics, with regulated market approvals (USFDA, EDQM, ANVISA, Health Canada and others) and a global presence across 120+ countries supplying over 1,500 customers.

Q3 FY26 revenue was INR 2064 Mn (▲11% YoY) with strong profitability: EBITDA INR 720.8 Mn (34.9%) and PAT INR 496.8 Mn (24.1%), reflecting resilience driven by high‑margin niche APIs and export demand despite margin normalization from new product scaling and higher employee and other expenses.

Listed peers in Pharmaceuticals: Sanofi India Ltd, Jeena Sikho Lifecare Ltd, FDC Ltd, Senores Pharmaceuticals Ltd, Aarti Pharmalabs Ltd, Innova Captab Ltd.

Valuation & Returns

10 Jul 2026

At ₹856 a share on 10 Jul 2026, Supriya Lifescience Ltd (SUPRIYA) was valued at a price-to-earnings ratio of 32.94x against an industry P/E of 36.41x and a price-to-book of 6.91x on a book value of ₹123.85 per share as of Mar 2025. Solomo computes return on equity of 20.98% and return on capital employed of 27.61% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.

P/E
32.94x
Industry P/E
36.41x
P/B
6.91x
EPS (TTM)
₹25.98
Book value / share
₹123.85
ROE
20.98%
ROCE
27.61%
ROA
18.8%
Debt / equity
0.01x
Dividend yield
0.12%
EBITDA margin
36.85%
52-week range
₹545.65 – ₹1,085.5

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Supriya Lifescience Ltd (SUPRIYA) reported revenue of ₹828 crore, net profit of ₹209 crore and earnings per share of ₹25.98. That compares with revenue of ₹696 crore and net profit of ₹188 crore in Mar 2025. Figures are standalone, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹277 crore and net profit ₹74 crore (standalone).

Standalone annual results for Supriya Lifescience Ltd (SUPRIYA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)530461570696828
Net profit (₹ cr)15290119188209
EPS (₹)18.8611.1714.823.3525.98
Compound annual growth for Supriya Lifescience Ltd (SUPRIYA). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth17.28%16.81%9.93%22.12%
Profit growth47.48%20.71%7.38%57.80%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 68.3% of Supriya Lifescience Ltd (SUPRIYA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 6.19% and domestic institutional investors (DII) hold 5.3%. Market capitalisation was ₹6,889 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2021.

Largest disclosed public shareholders in Jun 2026: Cohesion Mk Best Ideas Sub-Trust 2.98%, Aditya Birla Sun Life Insurance Company Limited 2.19%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202668.3%-6.19%5.3%31.7%
Mar 202668.3%-5.16%5.7%31.7%
Dec 202568.3%-5.2%5.01%31.7%
Sep 202568.3%-5.46%5.22%31.7%
Jun 202568.3%-6.78%4.86%31.7%
Mar 202568.3%-7.19%4.26%31.7%
Dec 202468.3%-6.52%4.92%31.7%
Sep 202468.3%-6.03%5.45%31.7%
Every quarter since Dec 2021 Filing data, not investment advice.